Regeneron Pharmaceuticals Inc. buy phonebroker
Start price
24.06.15
/
50%
€458.60
Target price
20.07.15
€490.00
Performance (%)
11.97%
End price
20.07.15
€513.50
Summary
This prediction ended on 20.07.15 with a price of €513.50. The BUY prediction by phonebroker finished with a performance of 11.97%. phonebroker has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 0.129% | 0.129% | -16.036% | -12.842% |
| iShares Core DAX® | 1.803% | 0.496% | 18.553% | 66.100% |
| iShares Nasdaq 100 | 0.429% | -0.410% | 8.908% | 102.921% |
| iShares Nikkei 225® | 0.708% | -3.799% | 12.088% | 42.472% |
| iShares S&P 500 | 0.288% | -0.218% | 3.736% | 63.299% |
Comments by phonebroker for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Spekulativ kaufen
Gute Nachrichtenlage, schöne Kursentwicklung.
(Vom Mitglied beendet)